A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Feb 28, 2014

Astellas Announces Stock Split and Partial Amendment to the Articles of Incorporation

Read more about Astellas Announces Stock Split and Partial Amendment to the Articles of Incorporation
Feb 5, 2014

Astellas: Reorganization of Astellas’ Global Management Structure

Read more about Astellas: Reorganization of Astellas’ Global Management Structure
Feb 2, 2014

AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib

Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014

CAMBRIDGE, MASS. and TOKYO, JAPAN, February 14, 2014 – AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and...

Read more about AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Jan 28, 2014

MEDIVATION AND ASTELLAS ANNOUNCE FINAL RESULTS FROM THE PHASE 3 PREVAIL TRIAL OF ENZALUTAMIDE IN MEN WITH METASTATIC PROSTATE CANCER PROGRESSING ON ANDROGEN DEPRIVATION THERAPY

SAN FRANCISCO, CA AND TOKYO, JAPAN – January 28, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced final results on the primary and secondary efficacy...

Read more about MEDIVATION AND ASTELLAS ANNOUNCE FINAL RESULTS FROM THE PHASE 3 PREVAIL TRIAL OF ENZALUTAMIDE IN MEN WITH METASTATIC PROSTATE CANCER PROGRESSING ON ANDROGEN DEPRIVATION THERAPY
Jan 17, 2014

Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

TOKYO, January 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has obtained the marketing approval of selective SGLT2...

Read more about Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts